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Summary 
Parenteral nutrition (PN) provides intravenous nutritional support to 
patients with reduced gastrointestinal function. A PN bag comprises the 
basic building blocks of the food groups: lipids, glucose, amino acids, 
vitamins, electrolytes and trace elements. Recently there has been an 
increase in demand for extended storage periods for PN bags, to ease 
management of an increasing home care market. Prior to a PN formulation 
being deemed safe for a patient, a laboratory simulation is carried out on 
the proposed admixture under the requested storage and administration 
conditions. Currently only the physical stability is assessed; physical 
testing provides no information on the quantity of each component 
remaining in the bag after storage. Consequently, there is a need for 
assessing the chemical stability of PN to indicate the quantity of each 
component that remains in the PN bag. 
A commonly used amino acid product, Aminoven® 25, contains 16 amino 
acids; this work aimed to develop a HPLC assay capable of quantifying the 
amino acids in an aqueous PN bag containing Aminoven® 25. Fluorescence 
detection was used as it is a highly selective method of detection, which 
was preferable due to the number of components in PN. To detect the 
amino acids, as they don’t naturally fluoresce, derivatization was carried 
out using ortho-phthalaldehyde to form a fluorescing derivative. The 
developed assay resulted in validation of thirteen of the amino acids in 
Aminoven® 25. In addition, the method was shown to be unaffected by the 
iv 
 
presence of aqueous PN components, so this method is suitable for 
quantifying thirteen amino acids in aqueous PN containing Aminoven® 25. 
This assay can be used for assessing the stability during stability testing 
and confirming the quantity of amino acids after compounding for quality 
control release. 
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1.1 Parenteral Nutrition 
Parenteral nutrition (PN) provides intravenous nutritional support to 
patients with reduced gastrointestinal (GI) function. The National Institute 
for Health and Care Excellence (NICE) recommends that PN should be 
considered if patients are malnourished or at risk of malnutrition, when 
combined with restricted oral and/or enteral access and a non-functioning 
or perforated GI tract (NICE 2006). PN may be used as complete 
nutritional intake, but also to supplement patients who are unable to fully 
meet their nutritional requirements orally or enterally. Where possible, it 
is preferable to feed via the oral or enteral route; a pathway showing the 
stages that result in administration of PN is shown in figure 1.1. Conditions 
that commonly cause impairment of the GI tract include short bowel 
syndrome and fistulas. PN formulations can be administered to neonates, 
paediatrics and adults on a short or long-term basis, in hospital and at 
home. Individual requirements are determined by numerous factors, for 
example: patient weight, activity level, underlying conditions and location 
of catheter. Patients who require PN on a long-term basis, usually at home, 
have an individualised regimen and are regularly monitored by a 
multidisciplinary team for signs of malnutrition. Short bowel syndrome is 
the most common indication in the UK for home PN, accounting for 59 % 
of all home PN patients in 2010 (Smith et al. 2011). In 2010 the British 
Artificial Nutrition Survey found that in the UK approximately 800 people 
were receiving PN at home. The modal age for home PN patients in the UK 
is 51-60 years of age (Smith et al. 2011).  
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1.2 Components of Parenteral Nutrition 
In order to meet the nutritional requirements of a patient receiving PN, 
the admixture comprises the basic building blocks of the necessary food 
groups. PN admixtures may include amino acids, lipids, glucose, water, 
electrolytes, vitamins, and trace elements; this complex formulation can 
result in upwards of 50 components being mixed together. Generally 
speaking there are two types of PN, aqueous and lipid; the main difference 
being the inclusion of lipid products in lipid PN.  
Is patient malnourished or at risk of 
malnourishment? 
NICE define malnourishment as any of the 
following: 
-  BMI < 18.5 kg/m2 
- > 10 % unintentional weight loss in 
last 3-6 months 
- BMI < 20 kg/m2 and > 5 % 
unintentional weight loss in last 3-6 
months 
Yes 
No 
No further action 
required 
Does patient have an unsafe swallow or 
poor oral intake? 
No Oral nutritional 
support 
Yes 
Does patient have a non-functioning or 
perforated gastrointestinal tract? 
No 
Yes 
Enteral nutritional 
support 
Parenteral nutritional 
support 
Figure 1.1 Overview of decision pathway leading to prescription of PN (Adapted from (Manuel & 
Maynard 2009)). 
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1.2.1 Amino Acids 
Humans cannot store amino acids, unlike fat and glucose, so they must be 
provided readily from nutrition. NICE (2006) recommends a nitrogen 
intake of 0.13-1.24 g/kg/day for adults receiving PN. ESPGHAN (2005a) 
recommends 1.5 to 4 g/kg/day for preterm infants and 1 to 2.5 g/kg/day 
for children. The amino acid requirements of a patient receiving PN is 
reduced compared with that of a patient obtaining nutrition orally or 
enterally; it is estimated that 30-50 % of ingested amino acids are not 
available to extra-intestinal tissues as they are utilised within the 
intestinal mucosa (Wu 1998). Duran (2005) found that parenteral feeding 
causes minimal intestinal atrophy in infants receiving PN; this is similar to 
findings by Raul et al. (1984), who studied parenterally fed rats. 
1.2.2 Lipids 
Lipid emulsions are included in PN as an energy source and to provide 
essential fatty acids, which are those that the body cannot synthesise; 
these are linoleic and α-linolenic acids. Currently there are a number of 
lipid emulsions available, where the oil is derived from plant or animal 
sources, to provide a variety of hydrocarbon chain lengths. Soybean oil is 
commonly found in PN lipid emulsions to provide the essential fatty acids 
linoleic acid and α-linolenic acid. Emulsions may also contain palm kernel 
oil, olive oil and fish oil. Lipid emulsions used in PN have an average 
globule size diameter of 0.25-0.5 µm, similar to the diameter of naturally 
occurring chylomicrons (Pertkiewicz and Cosslett 2000).  
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1.2.3 Glucose 
Glucose is not essential due to human’s endogenous ability for 
gluconeogenesis; however, it is used as a source of calories in PN. Excess 
glucose intake can cause lipogenesis, resulting in fat deposition (Wolfe et 
al. 1980). In addition, high levels of blood glucose have also been linked to 
an increase in infection related mortality in patients receiving PN (Berghe 
2004). In the UK, intravenous glucose solutions are available in a range of 
concentrations, 5 % to 70 %; this allows glucose and volume needs of a 
patient to be met. 
1.2.4 Electrolytes 
Electrolytes included in PN are: salts of sodium, potassium, calcium, 
magnesium and phosphate. Requirements are met with additions of 
individual salt solutions; the monovalent cations in PN, sodium and 
potassium, are primarily sourced from chloride salts. Magnesium is added 
as magnesium sulphate. There are a variety of calcium and phosphate 
containing products available as these polyvalent ions particularly affect 
stability of PN; providing a range of products delivers the greatest 
likelihood of providing PN that is both clinically appropriate and 
physically stable.  
1.2.5 Vitamins 
Vitamins are categorised into fat-soluble and water-soluble vitamins. Fat 
soluble vitamins include A, D, E and K; water soluble vitamins include B 
vitamins, and vitamin C. Products containing fat-soluble and water-soluble 
vitamins, separately and together, are available. 
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1.2.6 Trace Elements 
There are fifteen trace elements that are known to have physiological 
roles, however, only ten are generally considered to be essential to 
consume and included in PN: zinc, copper, selenium, chromium, iron, 
manganese, molybdenum, fluorine, cobalt (as a component of 
hydroxocobalamin) and iodine.  
1.3 Physical Stability of Parenteral Nutrition 
The large number of components in a PN formulation results in a high 
likelihood of interactions between components; so assessing the stability 
of an admixture is paramount when considering patient safety. As 
increasing numbers of patients manage their PN at home there is an 
increasing demand for extended storage times, resulting in reduced waste 
and less frequent deliveries, which in turn reduces costs. The primary 
physical stability issue when considering aqueous PN is the formation of 
precipitates; for lipid PN it is the integrity of the lipid emulsion. 
Precipitates in aqueous PN are commonly caused by reactions involving 
electrolytes, and less commonly trace elements. In 1994 the Food and 
Drug Administration (FDA) issued a safety alert due to two deaths and two 
patients in respiratory distress that occurred as a result of receiving PN. 
Autopsies revealed that the two deceased patients presented with 
microvascular pulmonary emboli containing calcium phosphate. Other 
reported deaths due to the infusion of calcium phosphate have been 
documented (Reedy 1999; Hill et al. 1996). Instability of a lipid emulsion 
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can ultimately cause the lipid emulsion to crack, resulting in free oil. The 
FDA and British Pharmaceutical Nutrition Group recommend the use of in-
line filters during the administration of PN to effectively protect the 
patient from microbial contamination and stability problems related to 
PN. 0.2 µm and 1.2 µm filters are recommended for aqueous and lipid PN 
respectively.  
1.3.1 Physical Stability Issues 
Aqueous PN instability is likely to result in precipitate formation; the most 
researched and documented is calcium phosphate. As previously 
mentioned, there have been several fatalities reported due to the infusion 
of PN containing calcium phosphate precipitates. Calcium phosphate 
precipitation mainly occurs in admixtures with particularly high 
concentrations of calcium and phosphate; these include small volume 
regimens for adults with a low fluid requirement, infants and neonates 
(Ronchera-Oms et al. 1996). Calcium phosphate formation is affected by a 
complex interaction of numerous factors: pH, glucose concentration, 
amino acid composition and concentration, source of calcium and 
phosphate salts, time elapsed since admixing and temperature 
(Pertkiewicz and Cosslett 2000).  
It is widely accepted that pH is the most important influence on the 
formation of calcium phosphate precipitates due to its effect on the 
phosphate ions. In PN, monobasic and dibasic phosphate ions can exist; 
monobasic ions are commonly seen at a lower pH (< 6.4), whereas dibasic 
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phosphate ions are formed at higher pH. Formation of dibasic calcium 
phosphate is not immediate and occurs during storage of the PN bags 
(Pertkiewicz and Cosslett 2000). Calcium phosphate formed with 
monobasic phosphate has a solubility of approximately 18 g/L, whereas 
when formed with dibasic phosphate it has a solubility of approximately 
0.3 g/L (Parikh et al. 2005). The addition of amino acid solutions 
decreases the pH of PN and reduce the likelihood of calcium phosphate 
formation. Furthermore, amino acids interact with electrolytes to form 
soluble complexes, thereby improving stability by reducing the number of 
free calcium and phosphate ions (Manning and Washington 1992).  
In addition to calcium phosphate, trace elements have also been linked to 
precipitation issues in PN; though little research has been carried out to 
identify their prevalence and mechanisms. Allwood et al. (1998) have 
shown that a reaction between copper and cysteine is more likely when 
there are no vitamins and air is present; suggesting that vitamins and the 
exclusion of air have a protective effect. The authors also demonstrated 
that a reaction between iron and phosphate is less likely with an increased 
amino acid concentration and the addition of vitamins. Manganese and 
zinc have been reported to react with phosphate to form precipitates 
(Allwood and Greenwood 1992). Finally, selenium has been shown to 
precipitate in PN. Selenium is added to the admixture as the soluble 
selenite ion; which is selenium in the +IV oxidation state. In PN, ascorbic 
acid reduces selenite to insoluble selenium; the effect is more pronounced 
in the presence of copper (Postaire et al. 1989). 
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In lipid PN the lipid emulsion is at risk of physical instability, and may 
present in three stages: creaming, coalescence and cracking. Creaming 
presents as a white layer at the top of a bag; coalescence is the generation 
of larger lipid droplets; cracking occurs when free oil is released from the 
emulsion. Creaming is safe if the cream layer disperses when agitated; 
coalescence and cracking are irreversible and the bag is unsafe to 
administer (Pertkiewicz & Cosslett 2000). High concentrations of amino 
acids and glucose improve lipid stability and reduce the tendency for 
creaming.  
1.3.2 Extrinsic Factors Affecting Parenteral Nutrition Physical Stability  
The physical instability in PN discussed above is influenced by extrinsic 
factors. These include light, temperature, bag material and method of 
filling.  
Light and temperature can catalyse reactions and increase degradation 
rates (Hempoonsert et al. 2010; Allwood 2000; Keerati-u-rai and Corredig 
2009); to overcome these issues bags are stored in pharmaceutical 
refrigerators after compounding and light impermeable covers can be 
used over the bags during administration. Refrigerating PN can extend the 
shelf life, which is especially important for allowing transportation and 
delivery time for home PN patients. 
Bag material plays a role in PN stability; ethylene vinyl acetate bags are 
semi permeable to atmospheric gases, allowing gases to dissolve in PN 
(Allwood et al. 1996), which may react with the components of PN. This 
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problem can be addressed in two ways: the compounded bag can be 
overwrapped in a gas impermeable material or the bag can be 
manufactured from a gas impermeable material (Allwood et al. 1996). 
Multilayer (ML) bags are commonly used as they are impermeable to 
gases, so prevent gases entering the bag after compounding. 
The method of filling affects the stability of an admixture as it determines 
the level of aeration during manufacture (Ball and Barnett 1996). The PN 
bag can be made using a compounder, or made manually. Compounders 
introduce more air which can react with components of PN and with ML 
bags becoming more common place, any dissolved air is retained in the 
bag. Mixing order can also have a detrimental effect on the stability of PN; 
for example, calcium and phosphate products should not be added 
consecutively as it is likely that calcium phosphate will form. Care must be 
taken to ensure lines are flushed between products that are known to 
react. 
1.3.3 Stability Indicating Methods  
Currently only the physical integrity of a PN formulation is assessed to 
determine whether it is safe for administration. Stability testing 
procedures for aqueous PN involves visual inspection and monitoring the 
change in turbidity, pH and colour of the solution; tests for lipid PN are 
visual inspection, particle size analysis, microscopy and pH. Once the 
formulation has been shown to be stable, it may be replicated by homecare 
companies or hospitals for administration to patients. PN compounded for 
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patient infusion is subject to more straightforward QC tests; before release 
for use the bags are weighed and visually inspected.  
During stability testing there is no routine quantification of individual 
components prior to deeming an admixture safe for a patient. Recently 
there has been an emerging interest in the chemical stability of individual 
components in PN. There are two aspects to monitoring the chemical 
stability; firstly, to ensure that the patient is receiving the expected dose, 
and secondly to be aware that if there is significant degradation this will 
result in degradation products, some of which could be harmful. One 
addition to PN that has received little attention is the amino acids, they are 
important for the integrity of the PN formulation and for the patient so 
need researching.  
1.4 Amino Acids 
1.4.1 Amino Acid Biochemistry 
Amino acids are characterised by a primary amino group, a carboxyl group 
and a hydrogen atom attached to the α-carbon atom; the general formula 
for an amino acid is shown in figure 1.2.  
 
Figure 1.2 General formula of an amino acid 
 
 
R 
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The R group of an amino acid is charged, polar or non-polar in nature and 
may be aliphatic, aromatic or heteroaromatic. The different structures of 
the amino acids are demonstrated in table 1.1. All amino acids are chiral, 
except for glycine as its R group is a single hydrogen atom. Chirality results 
in two enantiomers, for amino acids these are termed L and D; the L-
configuration is naturally occurring.  
There are two compounds that are included when discussing amino acids 
that are not truly amino acids. Proline is classified as an imino acid, 
however is generally considered as an α-amino acid, whereby the amino 
group is involved in the closure of the pyrrolidine ring. Taurine is not an 
amino acid as it does not have a carboxyl group, but it is often referred to 
as one; as it does contain an amino group, more correctly it is an amino 
sulphonic acid.  
  
 13  
Table 1.1 Structures of amino acids 
 
Charged side chains 
 
 
Arginine 
 
Aspartic Acid 
 
Glutamic Acid 
 
Histidine 
 
Lysine 
 
Polar side chains 
 
 
Asparagine 
 
Glutamine 
 
Serine 
 
Threonine 
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Non-polar side chains 
 
 
Alanine 
 
Cysteine 
 
Glycine 
 
Isoleucine 
 
Leucine 
 
Methionine 
 
Phenylalanine 
 
Tryptophan 
 
Tyrosine 
 
Valine 
 
Other 
 
 
Proline 
 
Taurine 
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1.4.2 Amino Acids in Nutrition 
Amino acids are the building blocks of proteins, and are involved in 
numerous roles within the body. Amino acids are categorised as essential, 
non-essential and conditionally essential. Essential amino acids are those 
which cannot be synthesised by the body; non-essential amino acids can 
be synthesised by the body, often from other amino acids; conditionally 
essential amino acids are those which are essential for some patients, 
often resulting from an underlying condition or due to age. Deficiency in 
an essential amino acid results in the body breaking down its own protein 
to obtain the amino acid. Humans can endogenously synthesise twelve of 
the twenty-one required amino acids, the remaining nine, the essential 
amino acids, must be provided by food intake. The essential amino acids 
are histidine, isoleucine, leucine, lysine, methionine, phenylalanine, 
threonine, tryptophan and valine. The non-essential amino acids are 
alanine, asparagine, aspartic acid, glutamic acid, serine and taurine. 
Several amino acids are considered conditionally essential: arginine, 
glycine, cysteine, tyrosine, glutamine and proline. Endogenous arginine 
and glycine synthesis does not compensate for inadequate intake or 
depletion, so can be required from nutrition (Castillo et al. 1994; Wang et 
al. 2013). New-borns require exogenous cysteine until they mature 
enough to synthesise the amino acid from methionine (Gaull et al. 1972), 
therefore cysteine is considered conditionally essential for this age group. 
Patients with liver disease also require exogenous cysteine. In addition, 
patients with liver disease require exogenous tyrosine; it may also be 
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essential for premature infants (Manning and Washington 1992). 
Glutamine is considered conditionally essential for patients whose bodies 
are in a stressed state and unable to meet the glutamine demands (Lacey 
and Wilmore 1990). Whilst proline is often categorised as a conditionally 
essential amino acid, no information detailing the instances when it 
becomes essential have been found. 
1.4.3 Amino Acids in Parenteral Nutrition 
Amino acids are generally thought of as improving the stability of PN, 
however little is documented about their susceptibility to reactions that 
may result in their degradation.  
Amino acid solutions exert a protective influence on PN admixtures due to 
their buffering capacity (Pertkiewicz and Cosslett 2000); increased 
concentrations of amino acids improve the protective effect by enhancing 
the buffering capacity (Allwood and Kearney 1998). Amino acids solutions 
also decrease the pH of a PN admixture, which decreases the likelihood of 
calcium phosphate forming; the buffering capacity of amino acids helps 
maintain the lower pH. 
Glutamine is unstable in solution and is not soluble at high concentrations; 
consequently, it is not included in standard amino acid solutions. In order 
to meet the needs of severely ill patients, for whom glutamine may have 
become conditionally essential, manufacturers have developed synthetic 
dipeptides of glutamine and alanine (Dunnett 2007). The synthetic 
dipeptides are stable in solution but rapidly hydrolyse in the plasma after 
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intravenous infusion, thereby allowing the inclusion of glutamine in 
parenteral nutrition (Ackher et al. 2000). 
One study has shown that whilst riboflavin has a protective effect on 
glycine and leucine, it has a detrimental effect on methionine, proline, 
tryptophan and tyrosine (Bhatia et al. 1983). 
A well-documented reaction involving amino acids is the Maillard 
reaction; the amino group of an amino acid reacts with the aldehyde group 
of a reducing sugar (glucose in PN). The reaction is enhanced with time, 
elevated temperatures and increased pH (Mirtallo et al. 1981). The 
Maillard reaction is characterised by a browning effect, this colour change 
occurs at later stages of the reaction and also indicates that insoluble 
compounds have formed (Laegeler et al. 1974). The initial stages of the 
reaction are normally colourless, so observing colour change is not an 
ideal method for monitoring the initial stages of the Maillard reaction. In 
the later stages of the Maillard reaction, when the solution has become 
dark brown, the reacted amino acid has been destroyed (Moughan 2003). 
It is possible for the early stages of the reaction to be reversed under 
laboratory conditions using a strong acid; however, this reversion cannot 
be achieved in the body. It has been shown that when Maillard products 
are given parenterally approximately 90 % of the products are excreted in 
the urine (Stegink et al. 1981). The presence of Maillard products in PN 
has also been linked to an increase in zinc excretion; most likely due to 
zinc chelating with the Maillard products (Freeman et al. 1975). 
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A study by Fry and Stegink (1982) investigated the formation of Maillard 
products in a formulation of heat sterilised glucose and amino acids, with 
and without electrolytes, for one, seven and thirty days at 4 oC and 25 oC. 
The greatest average loss was 7.43 % which was seen after thirty days at 
25 oC. The authors found that serine, threonine, tryptophan and 
methionine were the most likely to form Maillard products. 
Amino acids are also susceptible to photo-oxidation, which, similarly to 
the Maillard reaction, can be identified by a darkening in colour over time 
(Allwood et al. 1996). Amino acids most susceptible to oxidation are 
cysteine, histidine, methionine, tryptophan and tyrosine (Li et al. 1995). In 
the presence of oxygen, two cysteine molecules oxidise to form cystine. 
Methionine is oxidized by atmospheric oxygen forming methionine 
sulphoxide and methionine sulphone (Patel et al. 2011); is has not been 
established if these chemicals are commonly formed in PN or if they are a 
potential risk to patients. In Europe, in order to extend the shelf lives of 
the amino acid products manufacturers purge solutions with an inert gas, 
for example nitrogen, and use gas impermeable packaging (Allwood et al. 
1996), but these benefits are lost once the packaging is opened and the 
solution is used in an admixture. Conversely, amino acids interacting with 
oxygen has a protective effect for ascorbic acid; ascorbic acid is susceptible 
to oxidation but amino acids compete for the oxygen (Kearney et al. 1998). 
However, the effects of oxygen should be limited due to the development 
of ML bags. Furthermore, if light protective bags are used this would 
further help protect the contents of PN bags from photo-oxidation. 
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Bouchoud and colleagues (2010) investigated amino acid stability in a 
formulation for neonates, composed of amino acids, glucose and 
electrolytes. They reported that there was no significant loss (>10 %) in 
amino acid concentration over a twelve-week storage period at 2-8 oC. The 
authors, however, failed to detail the individual amino acids that were 
quantified. The amino acid solution the authors used, Vaminolact®, 
contains proline and cysteine which are not detected with the method 
used in the study, this was not mentioned by the authors. Jeppsson & 
Tengborn (1987) found that lipid PN formulations with amino acids, 
glucose, electrolytes, vitamins and trace elements degraded by less than 
10 % after four weeks refrigeration followed by one day at room 
temperature.  Another study showed that after two months refrigeration 
of an amino acid, glucose, electrolyte and trace element formulation, none 
of the amino acids had degraded by more than 10 %.  However after six 
months refrigeration, only tyrosine, lysine and histidine retained more 
than 90 % of their original concentration; greatest losses were seen with 
alanine, proline, methionine, glycine, arginine and threonine (Nordfjeld et 
al. 1983). Whilst six months refrigeration is perhaps an unrealistic length 
of time that a bag would be stored, increasingly times of longer than two 
months are being seen. 
There are a few points to be considered when quantifying the amino acids 
in PN. Firstly, the implications of the degradation of amino acids; loss of 
amino acids means the patients will not receive the prescribed dose. 
Secondly, which amino acids should be routinely quantified as part of PN 
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stability testing; the literature on amino acid stability in PN is limited with 
no recent data to indicate their stability. Initially it would be ideal for all of 
the amino acids to be quantified, and then once the most reactive amino 
acids have been identified in a range of formulations, it may be possible to 
use some amino acids as markers for stability. As there is such limited 
data, and the majority of studies conducted on amino acid stability in PN 
omit many of the available PN components from the tested formulations, it 
is not currently possible to identify the most reactive amino acids to use as 
markers. Finally, another consideration for amino acid stability is thinking 
about what level of degradation would be clinically acceptable. Currently 
there are no guidelines to determine what would be an acceptable level of 
degradation to permit infusion of the admixture. Commonly in the 
pharmaceutical industry, a loss of more than 10 % is deemed 
unacceptable. 
1.4.4 Amino Acid Stability Indicating Methods 
It is clear that the stability of amino acids in PN needs to be monitored, the 
next section discusses the possible methods for this. High-performance 
liquid chromatography (HPLC) can separate, identify and quantify 
analytes, which makes it the ideal method when considering how to 
determine stability of an analyte in a complex matrix. HPLC can be utilised 
to separate the amino acids from the many other components in PN, to 
identify and quantify the amount of each amino acid in PN. Amino acid 
analysers are available; which are specialist, automated HPLC systems; 
unfortunately, they are hugely expensive. However, HPLC systems are 
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commonly found in analytical laboratories. A less specialised HPLC is a 
more practical method of analysis than an amino acid analyser as it is less 
costly, more likely to be found in Quality Control (QC) labs and has 
numerous alternative applications. If a suitable HPLC assay was available 
it is likely that quantification of amino acids would be carried out in a 
laboratory as part of determining chemical stability of a regimen and a QC 
department would have more interest in using the assay to confirm the 
quantity of amino acids added to the bag.  
Most amino acids lack intrinsic properties for adequate detection with 
HPLC without derivatisation. There are two well established approaches 
to amino acid derivatisation; ninhydrin derivatization and ortho-
phthalaldehyde (OPA) derivatization.  
Amino acid analysers use the ninhydrin method; amino acid analysers 
have been used previously for analysis in PN (Ronchera-Oms et al. 1995; 
Nordfjeld et al. 1983; Jeppsson and Tengborn 1987). The ninhydrin 
method involves ion-exchange chromatography and ultraviolet (UV) 
detection; this method is used by amino acid analysers. Derivatization of 
amino acids with ninhydrin results in the R-group being removed during 
the reaction so the same product is formed from each amino acid, so 
derivatization must occur after separation as a post-column reaction. An 
advantage of the ninhydrin method is it reacts with primary and 
secondary amino acids; however, the reaction will only occur at 
temperatures greater than 100 oC and the assay requires a long run time 
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to separate the amino acids prior to derivatization. An additional 
drawback to the ninhydrin method is the need for additional equipment to 
derivatize and detect the amino acids after separation (Wahl and 
Holzgrabe, 2016).  
The OPA method has been used for to detect amino acids in many 
biological samples: blood (Bartolomeo and Maisano 2006; Frank and 
Powers 2007); sweat (Delgado-Povedano et al. 2016); neurotransmitters 
(Perucho et al. 2015). OPA has also been used to detect amino acids in 
foodstuffs: tea (Hung et al. 2010); wine (Arrieta and Prats-Moya 2012); 
milk (Bennett et al. 2016). The OPA method uses pre-column 
derivatization and fluorescence detection; OPA does not itself fluoresce, so 
there are no issues of interference from excess reagent. Fluorescence 
detection is more sensitive and selective than UV detection. The selectivity 
is an important consideration when assaying PN, as there are numerous 
components; the sensitivity is less important as amino acids are present in 
abundance in PN. In addition, the OPA derivatization process is quick and 
occurs at room temperature.   
It has been reported that proline does not react with OPA and therefore 
cannot be detected with this derivatization method (Chernobrovkin et al. 
2004; Godel et al. 1984). It has also been reported that whilst cysteine 
reacts with OPA, the product is weakly fluorescent and unstable (García 
Alvarez-Coque et al. 1989; Bruckner et al. 1995; Chernobrovkin et al. 
2004; Godel et al. 1984).  
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There are alternative derivatization methods for amino acids that are less 
widely used, for example 9-fluorenylmethyl chloroformate (FMOC) and 
dansyl chloride (Dns-Cl).  
FMOC has been used to analyse alanine, arginine and glutamine in 
supplements (Baxter and Johns 2011). The reaction between FMOC and 
amino acids results in the formation of hydrolysis products that have 
similar properties to the derivatized amino acids, so interfere with 
detection; as does excess FMOC. It is possible to remove the hydrolysis 
products and excess FMOC with 1-aminoadamantane (ADAM); as ADAM is 
particularly hydrophobic this will elute slowly. It has been reported that 
using FMOC results in insoluble products (Heems et al. 1998) which would 
need to be removed from the sample before injection as they will cause 
damage to the column and reduce its lifespan. Dns-Cl has been used to 
analyse amino acids in food samples, but the sample preparation is over an 
hour and it is not possible to automate the derivatization process (Jia et al. 
2011; Tuberoso et al. 2015). 
There are also methods which can detect amino acids without 
derivatization. One method that has been used to detect underivatized 
amino acids in breast milk is HPLC electrospray ionization tandem mass 
spectrometry (ESI-MS/MS); the authors developed the method as a 
replacement for the ninhydrin method which resulted in a reduction in 
analysis time from two hours to two minutes (Sanchez et al. 2012). While 
analysis times are very short, it may be more useful as an identification 
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method than a quantitative method as repeatability was poor. Another 
detector that has been used without derivatization is a charged aerosol 
detector (CAD), however there is still sample preparation required to 
acidify some of the amino acids so they can be detected with CAD (Crafts et 
al. 2011; Socia and Foley 2016). Whilst there are methods that involve no 
derivatization, the detectors are not commonly found in laboratories so a 
method would not be widely available.  
Due to the variety of advantages and disadvantages of the discussed 
analysis methods, it is becoming more common to use a combination 
approach; for example, using two derivatizing reagents, OPA and FMOC 
(Buha et al. 2011; Garcia-Rodenas et al. 2016); or two detection methods, 
such as UV and CAD (Wahl and Holzgrabe 2016). 
1.4.5 Method Justification 
To be viable for use in any stability laboratory or QC laboratory, the 
method requires minimal and quick sample preparation, no specialist 
equipment and a detection method that detects only the amino acids in PN. 
Considering the requirements of the method, a pre-column method was 
selected over a post-column method as this reduces the amount of HPLC 
equipment required. From the selection of pre-column derivatizing 
reagents, OPA was chosen as it has a short reaction time, that occurs at 
room temperature. OPA has been considered the method of choice for 
amino acid analysis due to its simplicity, sensitivity, selectivity and short 
sample preparation time (Hanczkó and Molnár-Perl, 2003). Furthermore, 
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OPA forms derivatives of amino acids that fluoresce; the ability to use 
fluorescence detection over UV is important as it is more selective so less 
likely to suffer interference from the numerous other components in a PN 
formulation. There are no existing assays for amino acids in PN that use 
pre-column OPA derivatization and fluorescence detection. However, as 
this method has been utilised widely in the food industry and for biological 
samples, work from this field was a good basis for beginning method 
development for PN analysis.  
An application note (VWR 2012; appendix 1) that uses pre-column OPA 
derivatization with fluorescence detection is used initially as it was used 
for foodstuffs and provides detailed information about the derivatization 
procedure, so practically it is easier to replicate.  
1.5 Summary 
Amino acids are a vital part of PN, both for the patient and the physical 
stability of a PN bag. However, very little is known about their chemical 
stability in PN, which has potential implications for patient health. 
Therefore, there is a requirement to have a method that can identify and 
quantifying individual amino acids in the presence of other PN 
components, which can then be used to build up a stability profile for each 
amino acid. 
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1.6 Thesis Format 
The next two sections have been presented to detail method development 
(section 2) and method validation (section 3) separately. The method 
development details the adaptations to optimise the separation of amino 
acids in PN. Following this, the suitability and limits of the assay are 
reported in section 3. Both topics are then discussed in section 4. 
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1.7 Aims   
- Develop a stability indicating assay capable of quantifying amino 
acids in aqueous PN that is suitable for use in a stability laboratory 
or a QC laboratory 
1.8 Objectives 
- Minimise the number of steps in a derivatization process with OPA 
- Separate the amino acids in PN with HPLC and detect the 
fluorescing OPA derivatives in a short runtime 
- Validate the method with Aminoven® 25 and compare it with an 
aqueous PN formulation  
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2 Method Development  
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2.1 Initial Development Plan 
Initially the assay was trialled exactly as stated in the application note 
(VWR 2012), using Aminoven® 25, to determine whether this assay was 
worth continuing development. Aminoven® 25 was chosen as the amino 
acid solution as it is widely used and there is no published stability data. 
Aminoven® 25 contains the amino acids listed in appendix 2. 
2.1.1 Chemicals 
HPLC grade acetonitrile and methanol (Fisher Scientific, Loughborough, 
UK). 3-Mercaptopropionic acid (≥98%), alanine (≥98%), ammonium 
acetate (≥98%), arginine (≥98%), glycine (≥98%), histidine (≥98%), 
hydrochloric acid (~37%), isoleucine (≥98%), leucine (≥98%), lysine 
(≥98%), methionine (≥98%), phthaldialdehyde, phenylalanine (≥98%), 
proline (≥98%), serine (≥98%), sodium tetraborate (99.99%), taurine 
(≥99%), threonine (≥98%), tryptophan(≥99%), tyrosine (≥99%) and 
valine (≥98%) (Sigma-Aldrich, Gillingham, UK). 
2.1.2 Sample Preparation 
Derivatization was carried out using the OPA reagent, borate buffer, 
hydrochloric acid and methanol, the reaction is shown in figure 2.1. A thiol 
is required as part of the OPA derivatization reagent, the two most 
commonly used are 2-mercaptoethanol and 3-mercaptopropionic acid (3-
MPA), the latter was chosen due to forming more stable compounds 
(Molnár-Perl, 2011). The OPA reagent consisted of 10 mg OPA, 0.9 ml 
methanol, 100 µl borate buffer and 10 µl 3-MPA; the OPA reagent was 
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made fresh every week due to reduced fluorescence intensity if kept 
longer (Buha et al. 2011). The borate buffer was made by dissolving 2.515 
g sodium tetraborate in 100 ml water and adjusting the pH to 9.5 with 1 N 
hydrochloric acid, then heating in boiling water for 5 minutes; this was 
used until it ran out.  
              
 
 
 
                        +2H2O 
Figure 2.1 Schematic of the reaction between amino acids, OPA and 3-MPA during 
derivatization. 
 
To prepare a sample for HPLC analysis, 10 µl of Aminoven® 25 (Fresenius 
Kabi, Runcorn, UK) was mixed with 0.5 ml 50 % methanol, 200 µl borate 
buffer and 100 µl OPA reagent, mixed and then left for 200 seconds. Next, 
+ + 
amino acid OPA 3-MPA 
2 minutes 
pH 9.5   
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100 µl of 0.75 N hydrochloric acid was added and mixed, and then finally 
0.5 ml 50 % methanol was added. This resulted in a sample too 
concentrated for the detector and overloaded it, causing the run to be 
terminated. The derivatized sample was diluted in 50 % methanol to a 
suitable concentration for the fluorescence detector.  
2.1.3 HPLC Assay 
The HPLC conditions were as follows: the run time was 65 minutes, the 
excitation wavelength (Ex) was 330 nm and the emission wavelength (Em) 
was 440 nm for the duration of the run. The injection volume was 10 µl. 
Two mobile phases were used in a gradient run (table 2.1): 50 mM 
ammonium acetate (pH 7) as A and methanol (HPLC grade) as B; with a 
flow rate of 1 ml/min. The ammonium acetate was prepared fresh every 
day. A Merck LiChroCart Purospher STAR RP-18e (5 µm) 250-4.5 mm 
column was used with a column oven at 40 oC. HPLC analysis was carried 
out on ThermoFinnigan SCM100, P2000 and F3000 and data were 
interpreted using Chromquest 4.2 Chromatography data system.  
Table 2.1 Mobile phase gradient elution 
 
 
 
 
The first chromatogram of Aminoven® 25 analysed with the conditions 
detailed above, is shown in figure 2.2A. Before continuing with improving 
Time (min) %B 
0 25 
5 25 
25 36 
49 75 
52 75 
52.1 25 
65 25 
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separation and determining the identity of each peak, a sample of an 
aqueous PN formulation containing Aminoven® 25 was injected to see if 
there was any interference from other PN products and whether this assay 
looked worth pursuing (the formulation used is detailed in appendix 3). 
The chromatogram was largely unchanged by the presence of the 
numerous other components in PN, see figure 2.2B.  
 
 
Figure 2.2 Initial HLPC analysis: 
A – Aminoven® 25 derivatised with OPA 
B – Aqueous PN formulation containing Aminoven® 25 derivatised with OPA 
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2.2 Peak Identification 
Using standards for each amino acid in Aminoven® 25, work began to 
identify which amino acid/s corresponded to each peak. Solutions were 
prepared daily using a standard dissolved in water then derivatized; 
chromatograms for each amino acid are shown in figures 2.3 to 2.17. 
Aminoven® 25 was then spiked with each amino acid at twice the 
concentration found in Aminoven® 25. 
 
Figure 2.3 Chromatogram showing OPA derivative of serine standard 
 
 
 
Figure 2.4 Chromatogram showing OPA derivative of threonine standard 
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Figure 2.5 Chromatogram showing OPA derivative of glycine standard 
 
 
 
Figure 2.6 Chromatogram showing OPA derivative of arginine standard 
 
 
 
Figure 2.7 Chromatogram showing OPA derivative of taurine standard 
Minutes
0 5 10 15 20 25 30 35 40 45 50 55 60
m
V
0
250
500
750
1000
1250
1500
1750
m
V
0
250
500
750
1000
1250
1500
1750
FL2000/FL3000-440nm
A01
Minutes
0 5 10 15 20 25 30 35 40 45 50 55 60 65
m
V
0
200
400
600
800
m
V
0
200
400
600
800
FL2000/FL3000-440nm
A01
Minutes
0 5 10 15 20 25 30 35 40 45 50 55 60
m
V
0
100
200
300
400
m
V
0
100
200
300
400
FL2000/FL3000-440nm
A01
A
b
so
rb
an
ce
 (
F
U
) 
A
b
so
rb
an
ce
 (
F
U
) 
A
b
so
rb
an
ce
 (
F
U
) 
Time (minutes) 
Time (minutes) 
Time (minutes) 
 35  
 
Figure 2.8 Chromatogram showing OPA derivative of alanine standard 
 
 
 
Figure 2.9 Chromatogram showing OPA derivative of tyrosine standard 
 
 
 
Figure 2.10 Chromatogram showing OPA derivative of histidine standard 
Minutes
0 5 10 15 20 25 30 35 40 45 50 55 60 65
m
V
0
200
400
600
800
1000
1200
1400
1600
m
V
0
200
400
600
800
1000
1200
1400
1600
FL2000/FL3000-440nm
A03
Minutes
0 5 10 15 20 25 30 35 40 45 50 55 60 65
m
V
0
200
400
600
800
1000
m
V
0
200
400
600
800
1000
FL2000/FL3000-440nm
A03
Minutes
0 5 10 15 20 25 30 35 40 45 50 55 60 65
m
V
0
20
40
60
80
m
V
0
20
40
60
80
FL2000/FL3000-440nm
A01
A
b
so
rb
an
ce
 (
F
U
) 
A
b
so
rb
an
ce
 (
F
U
) 
A
b
so
rb
an
ce
 (
F
U
) 
Time (minutes) 
Time (minutes) 
Time (minutes) 
 36  
 
Figure 2.11 Chromatogram showing OPA derivative of methionine standard 
 
 
 
Figure 2.12 Chromatogram showing OPA derivative of tryptophan standard 
 
 
 
Figure 2.13 Chromatogram showing OPA derivative of valine standard 
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Figure 2.14 Chromatogram showing OPA derivative of phenylalanine standard 
 
 
 
Figure 2.15 Chromatogram showing OPA derivative of isoleucine standard 
 
 
 
Figure 2.16 Chromatogram showing OPA derivative of leucine standard 
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Figure 2.17 Chromatogram showing OPA derivative of lysine standard 
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Figure 2.18 OPA derivative of Aminoven® 25 chromatogram with labels to show the identity 
of each peak 
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2.3 Reducing Run-Time 
The initial work was presented at an NHS QA Symposium, feedback 
suggested that there was interest in an assay for confirming the quantity 
of amino acids added during compounding, but the run time was too long 
to be feasible in that environment. Currently PN bag checks before release 
involve weighing and visually inspecting the bags. Neither of these 
measures indicates if the correct volume of an individual PN product has 
been added. A shorter run time may make this assay accessible to QC labs 
to confirm the correct amount of amino acids has been added. 
Firstly, to try and decrease the run time, the flow rate was increased from 
1 ml/min to 2 ml/min, but this had little effect so the column oven 
temperature was increased to 50 oC, but again this had little effect. As 
these simple changes were not successful, the next step was to adjust the 
mobile phase. Speeding up the rate of the increase in methanol, for more 
solvent strength, reduced the run time but also worsened the separation 
and resulted in co-elution of many peaks. The reduction in run time 
required was not possible with these condition changes. The organic 
solvent portion of the mobile phase was changed to include acetonitrile, as 
it is a stronger solvent so the amino acid derivatives should elute more 
quickly which will reduce the runtime. Initially a mix of methanol: 
acetonitrile (75 %: 25 %) was tried, and then the proportion of 
acetonitrile was increased by 25 % until mobile phase B was 100 % 
acetonitrile. The inclusion of acetonitrile decreased the run time and 
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maintained reasonable separation. With 100 % acetonitrile, the threonine 
and glycine peak slightly split (figure 2.19), this was the first time it had 
been possible to separate them.  
 
Figure 2.19 First time threonine and glycine OPA derivatives peak split 
 
Initially the gradient conditions were kept the same as previous (table 
2.1); as expected this significantly reduced retention times and caused co-
elution of peaks because acetonitrile is a stronger solvent than methanol.  
Subsequently the gradient was adjusted by reducing the speed that the 
concentration of acetonitrile increased, however even when the run 
became isocratic with 25 % acetonitrile there was still co-elution. So, the 
starting concentration of acetonitrile was reduced in 5 % intervals; 
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acetonitrile was 5 %. This resulted in glycine and threonine successfully 
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separation, shorter gradient delay times were tried but this resulted in 
worse separation. 
With the starting mobile phase conditions optimised adjusting the rest of 
the mobile phase amounts was done by adding each subsequent amino 
acid then tweaking and extending the assay for each additional amino acid. 
Where amino acids were co-eluting the rate of increase of acetonitrile 
concentration was slowed; if an amino acid was eluting a long time after 
the previous one, the rate the acetonitrile concentration increased sped 
up. Work began on serine, glycine, threonine and arginine; these were well 
resolved from each other, as shown in figure 2.20. Taurine was then added 
to the sample and separated, as shown in figure 2.21. 
 
Figure 2.20 Chromatogram showing OPA derivatives of serine, glycine, threonine, arginine 
separated 
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Figure 2.21 Chromatogram showing OPA derivatives of taurine separated from arginine 
 
Unexpectedly when alanine was added to the sample, it now had a shorter 
elution time than taurine, as shown in figure 2.22, but they were still well 
resolved from each other. 
 
Figure 2.22 Chromatogram showing OPA derivatives of alanine separated from arginine and 
taurine 
 
When histidine was added, no additional single resolved peak was 
detected, small peaks were detected at 9, 16.5 and 20.5 minutes, as seen in 
figure 2.23. 
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Figure 2.23 Chromatogram showing OPA derivatives of histidine added to serine, glycine, 
threonine, arginine, alanine and taurine  
 
Histidine was derivatized individually; this confirmed that no single peak 
was detected, as shown in figure 2.24. 
 
Figure 2.24 Chromatogram showing OPA derivative of histidine standard 
 
Valine and methionine were next to be added to the sample; it was 
confirmed that valine is the first to elute (figure 2.25). 
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Figure 2.25 Chromatogram showing OPA derivatives of valine and methionine separated 
 
Norvaline and phenylalanine were added to the sample. Norvaline was 
included in the assay development as it may be required at a later date as 
an internal standard during stability testing, so it seemed sensible to 
ensure it was separated from the Aminoven® 25 peaks at this stage. 
Norvaline eluted shortly after the methionine peak, as shown in figure 
2.26, the identity was confirmed by doubling the amount of norvaline in 
the sample, the peak area doubled.  
N.B. The split peaks in figure 2.25 and 2.26 are due to an old guard column. 
 
Figure 2.26 Chromatogram showing OPA derivatives of norvaline and phenylalanine 
separated from methionine 
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Isoleucine, leucine and lysine were added to the sample; they didn’t 
separate as well as the separations with methanol as mobile phase B. As 
shown in figure 2.27 there were co-eluting peaks at 28 minutes and a well 
resolved peak at 30.5 minutes. The identity of the peaks was confirmed by 
analysing each amino acid individually. As can be seen in figure 2.28 
isoleucine and leucine are well separated, with isoleucine eluting first.  
 
Figure 2.27 Chromatogram showing OPA derivatives of isoleucine, leucine and lysine 
 
 
 
Figure 2.28 Chromatogram showing OPA derivatives of isoleucine and leucine 
 
When phenylalanine was added it confirmed that it co-elutes with 
isoleucine (figure 2.29). To determine which was isoleucine and 
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phenylalanine, the amount of phenylalanine in the sample was doubled 
and the area of the second peak doubled, shown in table 2.2; this is the 
limiting pair. 
 
Figure 2.29 Chromatogram showing OPA derivatives of isoleucine, phenylalanine and 
leucine 
 
Table 2.2 Peak areas confirming the identity of isoleucine and phenylalanine peaks 
Isoleucine:Phenylalanine 
Isoleucine  
peak area 
Phenylalanine 
peak area 
1:1 3.502 2.854 
1:2 3.509 5.784 
 
When isoleucine, leucine and lysine were added a peak was detected at 18 
minutes (figure 2.27) which possibly is lysine, however when lysine was 
derivatized individually there is not a single peak but several small peaks 
(figure 2.30).  
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Figure 2.30 Chromatogram showing OPA derivative of lysine standard 
 
Tyrosine and tryptophan were confirmed as being detected, as shown in 
figure 2.31 and 2.32 respectively. 
N.B. The split peaks in figure 2.31 and 2.32 are due to an old guard column. 
 
Figure 2.31 Chromatogram showing OPA derivatives of tyrosine standard 
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Figure 2.32 Chromatogram showing OPA derivative of tryptophan standard 
 
To demonstrate the selectivity of the assay a sample of water was 
derivatized which resulted in no peaks; this confirms that the OPA alone is 
not fluorescent. A sample of underivatized Aminoven® 25 was also 
injected, unexpectedly there was a small peak at 7.5 minutes, see figure 
2.33. Aminoven® 25 contains glacial acetic acid and malic acid; malic acid 
has been reported as being detected by a fluorescence detector. 
 
Figure 2.33 Chromatogram of underivatized Aminoven® 25 
 
Once the process of separating each amino acid was complete, the time for 
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chromatogram of the identified amino acids in Aminoven® 25 when 
acetonitrile is used is shown in figure 2.34. 
 51  
 
Figure 2.34 Aminoven® 25 derivatised with OPA 
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2.4 Secondary Derivatization 
In Aminoven® 25, proline is the only amino acid that cannot react with 
OPA, as it does not have an amino group. In order to analyse proline it is 
possible to perform a two stage derivatisation; firstly with OPA, and then 
add FMOC to derivatize proline (Buha et al. 2011). Using two reagents 
simultaneously to derivatize all the amino acids in a sample will result in 
all the amino acids being identified in one injection. FMOC is insoluble 
with methanol, so acetonitrile replaced any methanol in the derivatization 
process. FMOC is known to form a precipitate when added to the reaction, 
so the amount required to react 1:1 with proline was used; there was no 
precipitate visible to the naked eye.  
2.4.1 Sample Preparation 
The FMOC reagent was made by dissolving 4 µg in 100 µl of acetonitrile; 
the FMOC reagent was usable for seven days when refrigerated (Buha et 
al. 2011). Samples were derivatized with the same method as detailed in 
section 2.1.2, however after the HCl was added 5 µl of FMOC reagent was 
added before dilution for injection. 
2.4.2 HPLC Conditions 
The FMOC derivative requires a different wavelength to the OPA 
derivatives, so this was added to the method (table 2.3).  
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Table 2.3 Gradient and wavelength conditions for OPA and FMOC derivatives 
Time (min) 
Acetonitrile (%) Wavelength 
(nm) 
0 5 
Ex 330 
Em 440 
2.5 5 
12 13 
25 20 
32 20 
Ex 266 
Em 310 
48 90 
48.1 5 
50 5 
 
2.4.3 Initial work 
Preliminary work showed that the addition of FMOC to the derivatization 
process allowed proline to be detected, see figure 2.35. However, when the 
two-stage derivatization was carried out with Aminoven® 25 the proline 
and FMOC peaks were less well defined, as shown in figure 2.36. FMOC 
does fluoresce unreacted, but is more hydrophobic than the OPA 
derivatives so does not interfere with separation of OPA derivatives, as 
seen in figure 2.36. Work on secondary derivatization was not pursued 
any further, development of the assay continued with solely OPA 
derivatization. 
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Figure 2.35 Chromatograms of initial work with FMOC and proline 
A – FMOC 
B – Proline derivatized with FMOC 
 
 
 
Figure 2.36 Chromatogram of Aminoven® 25 derivatized with OPA and FMOC 
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2.5 Repeatability 
Peak areas were decreasing with each subsequent intra-vial injection; this 
lack of consistency must be resolved in order for the assay to be viable as a 
stability indicating assay. The most likely reason is the lack of stability of 
the amino acid derivatives (García Alvarez-Coque et al. 1989; Fürst et al. 
1990); glycine and lysine derivatives are particularly susceptible to 
degradation  (Bruckner et al. 1995). This is worsened by the presence of 
any excess OPA and 3-MPA which form isoindoles that can attack the 
amino acid OPA derivatives. Amino acids, OPA and 3-MPA react in a 1:1:1 
ratio, so in theory they should be present in this ratio to minimise the 
formation of isoindoles; however, in the application of stability 
assessment, the quantity of amino acids is unknown after day 0.  
To overcome the poor stability of the derivatives, derivatisation needs to 
be carried out prior to each injection. Ideally, the derivatization procedure 
would be undertaken by an autosampler with on-board derivatization 
capabilities, as this ensures continuity throughout the preparation of 
amino acids for analysis (Bartolomeo and Maisano 2006). A suitable 
autosampler was purchased for this application. To use this function a 
program has to be written detailing the derivatization procedure. When 
writing the program on Chromeleon 7 to instruct the autosampler of the 
sequence for derivatization the same volumes as manual derivatisation 
were used, unfortunately this overloaded the detector. Additional wash 
steps were added to prevent contamination by the needle between 
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reagent vials and smaller volumes were programmed but this still 
overloaded the detector. Volumes of reagents were reduced again and 
again until the detector was no longer overloaded, however there was a 
large amount of disruption to the baseline that interfered with several 
peaks, particularly at shorter elution times, between 6 and 14 minutes, as 
can be seen in figure 2.37.  
 
Figure 2.37 Chromatogram of Aminoven® 25 with on-board OPA derivatization   
 
Fresh reagents were used, but no improvement was seen. It is probable 
that the cause is not the reagents or the sample, but the program written 
for the autosampler; however, after extensive investigation and discussion 
with the manufacturer no resolution was found. Therefore, validation of 
this assay was conducted with manual derivatization prior to each 
injection. 
2.6 Final Method 
As a summary of the work completed, a comparison of the method from 
the application note and the finished method that has been developed for 
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this project is shown in table 2.4, table 2.5 and figure 2.38. The validation 
process is then required to determine the limits of the assay. 
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Table 2.4 Comparison of methods, between application note and the final method 
 Method from 
application note 
Final method 
OPA reagent 
100 mg OPA 
 9 ml acetonitrile 
1 ml borate buffer 
100 µl 3-MPA 
16 mg OPA 
 0.9 ml acetonitrile 
0.1 ml borate buffer 
10 µl 3-MPA 
Run time (minutes) 65 35 
Column oven (oC) 40 50 
Mobile phase A 
50 mM ammonium acetate 
(pH 7) 
50 mM ammonium acetate 
(pH 7) 
Mobile phase B Methanol Acetonitrile 
Flow rate (ml/min) 1 2 
Ex - Em (nm) 330 - 440 330 - 440 
Injection volume (µl) 10 10 
Column 
Merck LiChroCart Purospher 
STAR RP-18e, 5 µm, 250-4.6 
mm 
Merck LiChroCart Purospher 
STAR RP-18e, 5 µm, 250-4.6 
mm 
HPLC equipment 
Pump: Thermo Finnigan 
SCM100  
Autosampler: Thermo 
Finnigan P2000 
FL detector: Thermo 
Finnigan FL3000 
Software: Chromquest 4.2 
Chromatography 
Pump: Dionex UltiMate 
3000 RS 
Autosampler: Dionex 
UltiMate 3000 RS 
Column Compartment: 
Dionex UltiMate 3000 RS 
FL detector: Thermo 
Finnigan FL3000 
Software: Chromeleon 7 
 
 
Table 2.5 Change in gradient conditions from the application note (left table) to the final 
assay (right table) 
 
 
 
 
  
Time (min) 
Acetonitrile 
(%) 
0 5 
2.5 5 
12 13 
25 20 
32 20 
32.1 5 
35 5 
Time (min) 
Methanol 
(%) 
0 25 
5 25 
25 36 
49 75 
52 75 
52.1 25 
65 25 
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Application note 
derivatization method 
 
Final method 
10 µl Aminoven® 25  5 µl Aminoven® 25 
      + 0.5 ml 50 % methanol 
+ 200 µl borate buffer pH 9.5 
       + 100 µl OPA reagent 
       + 0.25 ml 50 % acetonitrile 
+ 100 µl borate buffer pH 9.5 
       + 50 µl OPA reagent 
Mix and wait 200 seconds   Mix and wait 3 minutes 
         + 50 µl 0.75 N HCl          + 25 µl 0.75 N HCl 
Mix  Mix 
        + 0.5 ml 50 % methanol  10 µl of derivatized sample in                                
to 1.5 ml 50 % acetonitrile  
Mix  HPLC injection 10 µl 
   
HPLC injection 10 µl   
Figure 2.38 Comparison of derivatization method from the application note (left) and the 
final method (right) 
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3 Method Validation 
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3.1 Validating a HPLC Assay 
Method validation is a crucial part of developing a HPLC assay, as it 
demonstrates the suitability and limits of the assay. In this case, the 
International Conference on Harmonisation (ICH) document, Validation of 
Analytical Procedures Q2(R1), was used as a guide to validation processes. 
The ICH was set up to co-ordinate regulatory authorities for 
pharmaceutical product registration from Europe, Japan and the United 
States so that the same protocols are followed to eliminate duplicate 
testing in each area. As this assay is not for use for product registration, 
the ICH guidelines have only been used as a guide and the relevant parts 
followed. These are range, linearity, precision, accuracy, detection and 
quantitation limit; in addition, resolution and selectivity has been 
measured and a degradation study conducted. 
3.1.1 Range 
The range of a HPLC assay is defined as the upper and lower amounts of an 
analyte that show suitable accuracy, precision and linearity. The range for 
each amino acid used for assay validation is detailed in table 3.1. The ratio 
of the amino acids is fixed as Aminoven® 25 is a pre-prepared product.  
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Table 3.1 Upper and lower amounts of each amino acid for validation 
 Lower  
(ng/ml) 
Upper  
(ng/ml) 
Serine 247 739 
Glycine 476 1425 
Threonine 221 662 
Arginine 514 1540 
Alanine 643 1925 
Taurine 51 154 
Tyrosine 10 31 
lValine 142 424 
Methionine 98 293 
Tryptophan 41 123 
Isoleucine 142 424 
Phenylalanine 134 400 
Leucine 229 685 
 
3.1.2 Linearity 
Linearity is a measure of how accurately the detector responds to changes 
in concentration of the analyte. This is essential in a stability assay, as if 
the analyte degrades the reduction in peak area should be directly 
proportional to the loss of the amino acid. The ICH (2005) recommend 
that linearity should be determined using at least five different amounts of 
an analyte; the peak areas are then used to generate the calibration graph 
with a standard deviation error bar. Linearity is expressed as a value: R2, 
this is measure of how well the data points fit to a fitted regression line. To 
generate the calibration graph, the amount of amino acid derivatized was 
plotted against absorbance. Usually a R2 value greater than 0.999 is 
acceptable, though due to the number of analytes and the derivatisation 
steps, a value of 0.99 may be acceptable (Snyder et al. 1997). Figures 3.1 to 
3.13 show the calibration plots for each amino acid and the corresponding 
R2 value. 
 63  
 
Figure 3.1 Calibration plot of serine n=3 
 
 
 
 
Figure 3.2 Calibration plot of glycine n=3 
 
 
 
       
Figure 3.3 Calibration plots of threonine n=3.   
A – Calibration plot with five concentrations from 221 ng/ml to 662 ng/ml  
B – Calibration plot with four concentrations from 221 ng/ml to 552 ng/ml 
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Figure 3.4 Calibration plot of arginine n=3 
 
 
 
 
Figure 3.5 Calibration plot of alanine n=3 
 
 
 
 
Figure 3.6 Calibration plot of taurine n=3 
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Figure 3.7 Calibration plots of tyrosine n=3 
A – Calibration plot with five concentrations from 10 ng/ml to 31 ng/ml  
B – Calibration plot with four concentrations from 10 ng/ml to 26 ng/ml 
 
 
     
Figure 3.8 Calibration plots of valine n=3 
A – Calibration plot with five concentrations from 142 ng/ml to 424 ng/ml  
B – Calibration plot with four concentrations from 142 ng/ml to 353 ng/ml 
 
 
 
Figure 3.9 Calibration plot for methionine n=3 
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Figure 3.10 Calibration plot for tryptophan n=3 
 
 
     
Figure 3.11 Calibration plots for isoleucine n=3 
A – Calibration plot with five concentrations from 142 ng/ml to 424 ng/ml 
B – Calibration plot with four concentrations from 142 ng/ml to 353 ng/ml 
 
     
Figure 3.12 Calibration plots for phenylalanine n=3 
A – Calibration plot with five concentrations from 134 ng/ml to 400 ng/ml 
B – Calibration plot with four concentrations from 134 ng/ml to 334 ng/ml 
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Figure 3.13 Calibration plots for leucine n=3 
A – Calibration plot with five concentrations from 229 ng/ml to 685 ng/ml 
B – Calibration plot with four concentrations from 229 ng/ml to 572 ng/ml 
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and leucine; the R2 value improves considerably, this can be seen in figures 
3.3B, 3.7B, 3.8B, 3.11B, 3.12B and 3.13B. The altered calibration plot 
results in R2 greater than 0.99 for valine, phenylalanine and isoleucine; 
table 3.2 details the R2 and RSD values for the amino acids. 
Table 3.2 Linearity of amino acids in Aminoven® 25 
 Linearity 
(R2) n=5 
RSD (%) 
Linearity 
(R2) n=4 
RSD (%) 
Serine 0.9967 2.93   
Glycine 0.9986 2.74   
Threonine 0.7701 11.52 0.9891 3.62 
Arginine 0.9975 2.76   
Alanine 0.9976 2.98   
Taurine 0.9978 2.89   
Tyrosine 0.8840 11.67 0.9851 8.42 
Valine 0.9398 7.09 0.9920 3.03 
Methionine 0.9928 3.62   
Tryptophan 0.9980 8.02   
Isoleucine 0.9820 4.90 0.9943 3.42 
Phenylalanine 0.9615 6.43 0.9961 4.11 
Leucine 0.9718 8.69 0.9863 8.67 
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3.1.3 Accuracy 
Accuracy is defined as the agreement between the true value and the 
measured value. Values between 90 and 110 % are acceptable (Snyder et 
al. 1997). 
Table 3.3 Percentage of recovery  
 Recovery (% ± SD) 
Serine 99.68 ± 3.13 
Glycine 99.92 ± 2.17 
Threonine 100.74 ± 4.50 
Arginine 100.83 ± 2.74 
Alanine 100.37 ± 2.78 
Taurine 99.07 ± 2.74 
Tyrosine 100.87 ± 6.82 
Valine 98.59 ± 3.67 
Methionine 99.72 ± 4.53 
Tryptophan 102.15 ± 2.02 
Isoleucine 98.16 ± 3.46 
Phenylalanine 99.27 ± 2.26 
Leucine 100.67 ± 6.18 
 
All amino acids showed acceptable accuracy; as shown in table 3.3, values 
ranged from 98.16 % to 102.15 %. 
3.1.4 Precision 
Precision is a measure of how reproducible results are; this is measured in 
various ways and expressed as a relative standard deviation (RSD). The 
ICH guidelines define precision as; repeatability, intermediate precision 
and reproducibility (ICH 2005). Repeatability is the result of repeated 
injections over a short period of time, in this case three injections of the 
same sample were carried out immediately one after another (results 
shown in table 3.4). Intermediate precision is the measure of 
reproducibility within a laboratory, in this case samples were analysed on 
two different days and the results compared (results shown in table 3.4). 
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Reproducibility is the precision between laboratories; this has not been 
carried out as part of the validation process as it is not required according 
to the ICH guidelines (2005); however, would be required should another 
laboratory require this method. Suggested limits for precision vary, but 
the lower the RSD value the better. Less than 2 % is considered ideal 
(Paithankar 2013); however, this is a guideline for drug products so may 
be unnecessarily restrictive for this application. 
Table 3.4 Repeatability and intermediate precision RSD values for each amino acid 
 
Repeatability 
RSD % (n=3) 
Intermediate 
precision 
RSD % (n=5) 
Serine 2.41 2.81 
Glycine 2.89 3.40 
Threonine 2.02 3.48 
Arginine 3.07 3.54 
Alanine 3.34 3.60 
Taurine 2.91 2.98 
Tyrosine 5.81 21.98 
Valine 2.89 3.47 
Methionine 3.76 4.23 
Tryptophan 2.50 4.16 
Isoleucine 3.34 4.04 
Phenylalanine 3.03 3.23 
Leucine 4.61 4.89 
 
Repeatability of the amino acids ranged from 2.02 % to 5.81 % (table 3.4), 
although apart from tyrosine and leucine all were less than 4 %. The 
results for intermediate precision are similar to the repeatability, apart 
from tyrosine, which increases to 21.98 %. One of the injections on the 
second day of testing for the intermediate precision resulted in lower peak 
areas compared to the other injections; this data has been identified as an 
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anomaly and removed from the intermediate precision data. The peak 
areas for all six injections are detailed in appendix 4. 
3.1.5 Resolution and Selectivity 
Resolution is a measure of baseline separation of two peaks which is 
necessary for accurate integration. Determining resolution is not included 
in the ICH guidelines, but has been measured during the validation process 
due to the number of analytes. Resolution was calculated by Chromeleon 
using the following equation, which is based on the European 
Pharmacopeia method: 
RS = 1.18(T2 – T1) 
         (W501 + W502) 
Where:  
T1 / T2 are the retention times of the two peaks 
W501 / W502 are the time of the two adjacent peaks at 50 % of the peak 
height 
The resolution value for a peak indicates the resolution for that peak from 
the subsequent peak. The higher the RS value, the further apart the peaks 
are, consequently increasing resolution increases the run time, so the two 
must be balanced. A resolution greater than 1.5 indicates baseline 
resolution; however for samples containing more than ten analytes, as in 
this case, a value of Rs > 1 may be deemed acceptable (Snyder et al. 1997).  
Selectivity is a measure of the quality of the peak separation by 
determining how will analytes are chemically distinguished from one 
another. Selectivity values greater than 1 indicates good separation; a 
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value of 1 results from co-eluting peaks. Selectivity was calculated by 
Chromeleon using the following equation: 
α = T2 – T0 
           T1 – T0 
 
Where:  
T1/T2 are the retention times of the two peaks 
T0 is the dead time (time between injection and the solvent front) 
Table 3.5 Resolution and selectivity of amino acid peaks (n=3) 
 
RS 
(RSD %) 
α 
(SD) 
Serine - Glycine 
6.55 
(2.62) 
1.56 
(0.00) 
Glycine - Threonine 
1.96 
(0.59) 
1.07 
(0.00) 
Threonine – Arginine 
4.02 
(0.50) 
1.13 
(0.00) 
Arginine – Alanine 
5.87 
(0.95) 
1.17 
(0.00) 
Alanine – Taurine 
2.16 
(0.80) 
1.06 
(0.00) 
Taurine – Tyrosine 
8.82 
(1.61) 
1.24 
(0.00) 
Tyrosine – Valine 
5.51 
(0.46) 
1.37 
(0.00) 
Valine - Methionine 
2.17 
(1.07) 
1.04 
(0.00) 
Methionine – Tryptophan 
10.05 
(1.85) 
1.21 
(0.00) 
Tryptophan - Isoleucine 
1.39 
(2.31) 
1.02 
(0.00) 
Isoleucine - Phenylalanine 
0.94 
(2.22) 
1.02 
(0.00) 
Phenylalanine - Leucine 
4.07 
(0.74) 
1.08 
(0.00) 
 
Most peaks were well resolved, with a RS value greater than 1. As reported 
in table 3.5 isoleucine and phenylalanine did not resolve to baseline, as 
 73  
shown by the RS value of 0.93, so cannot be integrated separately. 
Selectivity values were all greater than 1, indicating good peak separation.  
3.1.6 Detection Limit and Quantitation Limit 
The limit of detection (LOD) is defined as the smallest amount of an 
analyte that can be distinguished from the baseline. The limit of 
quantification (LOQ) defines the smallest amount of an analyte that can be 
quantified with acceptable precision and accuracy under the stated assay 
conditions. The LOD and LOQ were calculated from the linearity plot by 
using the standard deviation of the response and the slope of the linearity 
plot. 
LOD and LOQ are calculated by: 
LOD = 3.3σ   LOQ = 10σ 
   S      S 
Where: σ = standard deviation of the response 
  S = slope of the calibration curve 
LOD and LOQ values for the amino acids detected are shown in table 3.6. 
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Table 3.6 Limit of detection and limit of quantification values 
 LOD (ng/ml) LOQ (ng/ml) 
Serine 56 169 
Glycine 70 212 
Threonine 95 287 
Arginine 100 304 
Alanine 123 373 
Taurine 9 28 
Tyrosine 5 16 
Valine 52 157 
Methionine 33 99 
Tryptophan 7 22 
Isoleucine 44 133 
Phenylalanine 34 104 
Leucine 110 335 
 
3.1.7 Degradation 
A stability indicating assay must be able to detect the analytes without 
interference from degradation products. In order to test this, a forced 
degradation study is conducted. Ideally during the degradation study the 
analyte/s should be degraded by approximately 10 % (Snyder et al. 1997). 
Degrading the product by this much will ascertain if any of the 
degradation products are detected during the assay, and if so whether 
they are co-eluting with the analyte/s for quantification. For this 
degradation study an uncapped bottle of Aminoven® 25 was exposed to 
air and sunlight, as amino acids are susceptible to degradation by these 
conditions (Allwood et al. 1996; Li et al. 1995; Patel et al; 2011). Peak 
areas reduced by 11 % or more (table 3.7) and there was no interference 
by the degradation products, see figure 3.14. 
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Table 3.7 Percentage of peak area reduction after forced degradation 
 Degradation (%) 
Serine 23 
Glycine 11 
Threonine 26 
Arginine 25 
Alanine 21 
Taurine 12 
Tyrosine 34 
Valine 38 
Methionine 29 
Tryptophan 38 
Isoleucine 35 
Phenylalanine 32 
Leucine 11 
 
 
Figure 3.14 Chromatogram of degraded Aminoven® 25 
3.2 Aqueous Parenteral Nutrition Containing Aminoven® 25 
The assay validation process was conducted with Aminoven® 25; 
however, the future application of this assay is to quantify amino acids in 
PN. In order to test the suitability of this assay for analysing PN samples a 
mock paediatric aqueous PN sample was made and derivatized; the 
formulation is detailed in table 3.8. Repeatability of aqueous PN was 
assessed and the peak areas were compared to Aminoven® 25 (table 3.9). 
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Table 3.8 Aqueous PN formulation used for comparison to Aminoven® 25 
Component Volume 
(ml) 
Aminoven® 25 (Fresenius Kabi, Runcorn, UK) 30 
Peditrace® (Fresenius Kabi, Runcorn, UK) 2 
Glucose 70% (Baxter, Newbury, UK) 5 
Sodium glycerophosphate 21.6% (Fresenius Kabi, Runcorn, UK) 5 
Water for injections (Fresenius Kabi, Runcorn, UK) 44 
Sodium chloride 30% (Torbay, Paignton, UK) 2 
Potassium chloride 15% (Torbay, Paignton, UK) 4 
Potassium acetate 49% (Torbay, Paignton, UK) 2 
Magnesium sulphate 50% (Torbay, Paignton, UK) 1 
Calcium chloride 1 mmol/ml (Martindale, Buckinghamshire, UK) 4 
Solivito® N (in WfI) (Fresenius Kabi, Runcorn, UK) 1 
 
Table 3.9 Repeatability of aqueous PN formulation (n=3) and aqueous PN formulation 
compared to Aminoven® 25 (n=6) 
 
Repeatability of 
aqueous PN 
RSD (%) 
Aminoven® 25 
compared to 
aqueous PN 
RSD (%) 
Serine 1.09 1.68 
Glycine 5.07 7.27 
Threonine 8.57 8.32 
Arginine 3.38 2.94 
Alanine 2.90 2.83 
Taurine 4.30 3.53 
Tyrosine 0.83 9.60 
Valine 6.21 7.13 
Methionine 1.40 2.79 
Tryptophan 5.18 3.78 
Isoleucine 2.11 6.39 
Phenylalanine 2.21 2.69 
Leucine 2.84 3.58 
 
Repeatability of the amino acids when derivatized as part of an aqueous 
PN formulation ranged from 0.83 % to 8.57 %. Precision results for the 
comparison of Aminoven® 25 with an aqueous formulation containing 
Aminoven® 25 were encouraging, RSD values ranged from 1.68 % to 9.60 
%. 
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To demonstrate that the peaks detected when analysing a PN sample 
represent only amino acids, another PN sample was made similar to that 
detailed in table 3.8, except Aminoven® 25 was replaced with water so if 
there were any remaining PN components reacting with OPA, they would 
be detected; no peaks were detected when this sample was derivatized 
and analysed, therefore none of the PN components in the formulation 
detailed it table 3.8 interfere with the assay. 
3.3 Summary 
Method validation has tested the suitability and limits of the method, by 
measuring the range, linearity, accuracy, precision, resolution, detection 
limit, quantitation limit, degradation and compatibility with aqueous PN. 
Serine, glycine, arginine, alanine, taurine, valine, methionine and 
tryptophan met the criteria set for the method validation. Tyrosine did not 
show adequate linearity or intermediate precision, therefore is not 
suitable for quantification in a stability study. Threonine and leucine did 
not show adequate linearity, although their R2 values were significantly 
improved by removing the upper amount from the range. Phenylalanine 
and isoleucine showed linearity, repeatability, intermediate precision and 
were above the quantification limit, however the two peaks did not 
resolve well enough from each other. 
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4 Discussion  
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4.1 General Discussion 
There is an increasing demand for longer shelf lives for PN bags, but the 
longer the bags are stored the greater the likelihood of reactions occurring 
within the bag. Therefore, there is a definite need for more comprehensive 
stability testing of PN to maintain patient safety and patient health. The 
MHRA have requested that data to indicate the chemical stability of PN 
components should be incorporated in to stability testing. It is possible 
that the concentration of components patients are receiving is less than 
the original dose added to the PN bag, so data on degradation of 
components will be vital for clinicians. Amino acids are a crucial 
component of PN, both for patient nutrition and the physical integrity of 
the PN formulation but there is limited data, particularly new data, on 
their stability in PN formulations. Previous methods have required lengthy 
sample preparation and analysis time, making them unpractical for 
generating the volume of chemical stability data required for clinical 
practice. In addition, previous methods have required expensive 
equipment, making it less accessible to stability and QC laboratories. 
This thesis shows the development and validation of a simple method to 
analyse amino acids in PN by their fluorescing OPA derivatives; resulting 
in a short sample preparation and analysis time, without the need for 
additional equipment. Aminoven® 25, which has not previously been the 
subject of analysis was used during this work. The method has been 
validated for thirteen of the sixteen amino acids in Aminoven® 25, in 35 
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minutes. Furthermore, the method has been shown to be applicable to 
aqueous PN formulations; this is the first time that a PN formulation 
containing amino acids, glucose, electrolytes, trace elements and vitamins 
has been analysed.  
Amino acids in Aminoven® 25 that were not successfully detected were 
proline, lysine and histidine. It is well known that proline cannot react 
with OPA due to the absence of an amino group, so it was expected that it 
would not be possible to detect proline with this method. Lysine may have 
sometimes been detected, but this was not confirmed. It has previously 
been noted that lysine has a poor fluorescent yield, therefore poor 
quantification (Godel et al. 1984) but it is not clear if this was the reason 
for the issues detailed in this thesis. Histidine was not detected with the 
final assay, so consequently could not be quantified during the method 
validation. The gain of a significantly reduced run time using acetonitrile 
resulted in the loss of two amino acids (histidine and lysine) being 
detected.  
Histidine and lysine were detected when methanol was part of the mobile 
phase; they were also both shown in the application note. This suggests 
that the change of mobile phase to acetonitrile may be the cause. This 
could be due to the change from a protic solvent, methanol, to an aprotic 
solvent, acetonitrile, and the way the derivatized histidine and lysine 
(which are both basic) interact with the solvents. Although it is worth 
noting that arginine is also basic and was detected when methanol and 
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acetonitrile were used. It has been reported that changes in HPLC 
conditions can affect histidine derivatives (Csampai et al. 2004). If a 
quaternary pump was available it would have been possible to introduce 
methanol to the mobile phase after glycine and threonine had separated; 
as histidine and lysine were both detected when methanol was the organic 
phase this may have resulted in their detection. 
Linearity values were greater than 0.985; linearity values are not stated in 
the VWR (2012) application note, or in previous papers that have analysed 
amino acids in PN with the ninhydrin method (Ronchera-Oms et al. 1995; 
Nordfjeld et al. 1983; Jeppsson and Tengborn 1987). However, analysis of 
foodstuffs and biological samples with OPA and fluorescence detection 
show a range of linearity values from 0.98 to 0.999 (Perucho et al. 2015; 
Hung et al. 2010; Buha et al. 2011; Frank and Powers 2007; Bartolomeo 
and Maisano 2006; Delgado-Povedano et al. 2016); suggesting that this 
method has acceptable linearity.  
Linearity was initially poor (R2 < 0.99) for threonine, tyrosine, valine, 
isoleucine, phenylalanine and leucine, although when the greatest 
concentration was removed from those calibration graphs valine, 
phenylalanine and isoleucine show increased linearity. The key reason 
identified as the cause of poor linearity at the upper range was the molar 
ratio between amino acids, OPA and 3-MPA; they were present in equal 
moles based for the uppermost range of the amino acids, and therefore in 
excess for lower concentrations of Aminoven® 25. It is plausible that not 
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all of the amino acids reacted when there is a not an excess of reagents; it 
has been reported that the derivatizing reagents should be present in a 
large excess (Lindroth and Mopper 1979).    
Precision results were larger than the 2 % often given as an acceptable 
limit; repeatability in the application note was 4 %. Other studies using 
OPA to analyse amino acids in foodstuffs and biological samples report 
repeatability values of 12 % (Herbert et al. 2000; Frank and Powers 2007) 
and 19.8 % (Pripis-Nicolau et al. 2001); precision of Aminoven® 25 and 
aqueous PN samples were considerably below these values, indicating that 
the repeatability values in this work are acceptable. Tyrosine showed the 
poorest precision results; it had the highest repeatability and intermediate 
precision results, 5.81 % and 21.98 % respectively.  Tyrosine has 
previously been reported as having a larger precision RSD than other 
amino acids, though not with values as high as 21.98 % (Arrieta and Prats-
Moya 2012). 
The method showed good separation in terms of resolution and selectivity, 
apart from isoleucine and phenylalanine which were co-eluting. The 
application note (VWR 2012) does not report any resolution values, 
however Buha et al. (2011) reported a RS < 1 for isoleucine and 
phenylalanine. 
The method does not always comply with regulatory method validation 
standards; however, these are intended for pharmaceutical product 
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registration. This method has validation results comparable to those 
reported when assaying amino acids in foodstuffs and biological samples. 
4.2 Limitations 
There are two main limitations with this method. Firstly, the samples had 
to be manually derivatized due to unresolvable issues with the on-board 
derivatization program for the autosampler. It has been widely reported 
that there are issues with repeatability when samples are manually 
derivatized; this may have affected the validation results. In addition, 
manually derivatizing is not ideal for conducting stability studies as this 
will limit the number of samples that can be run as it is time consuming for 
a member of staff. 
The second limitation is the assumption that the conversion rate when 
derivatizing the amino acids was 100 %. OPA derivatization of amino acids 
is a widely used method and publications do not routinely include an 
assessment of the conversion rate. However, one study has reported that 
the conversion rate of alanine, arginine, glycine, histidine, isoleucine, 
leucine, serine, threonine, tryptophan, tyrosine and valine is 96.6 % ± 6 % 
(Aminot and Kérouel, 2006). The authors found that reaction time and pH 
were the most important determinants of the reaction; the time and pH for 
the reaction in the method detailed in this thesis were optimal. Although 
the paper does not analyse the conversion rate of all the amino acids in 
Aminoven 25®, it is an indicator that the rate of conversion is high for this 
method. 
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4.3 Future work 
The next stage for this work is to resolve the issue with the program for 
the on-board derivatization sequence. If assessment of amino acid stability 
is going to be required on a regular basis the automated derivatization will 
be essential, as it significantly reduces labour time and will allow more 
samples to be analysed. In addition to the more practical benefits of the 
on-board derivatization, it will also improve the repeatability of the assay. 
Once the on-board capabilities are resolved there are some further steps 
to improve the assay. 
Firstly, as there was no obvious cause for the y-intercept of the calibration 
curve to be greater than zero, the linearity should be retested. Finally, 
development of the secondary derivatization process with FMOC needs 
completing; this will allow the detection of proline.  
4.4 Conclusion 
The MHRA has requested stability data for amino acids in PN as currently 
clinicians have no information on the degradation rates of amino acids in 
PN which ultimately may lead to poor patient outcomes. Previous methods 
used for analysis of amino acids in PN have long sample preparation and 
runtimes so are not feasible in a stability or QC laboratory where sample 
throughput is high. This work has resulted in a simple and quick method 
that is validated and appropriate for use in stability and QC laboratories. 
In the future, the method can be used as part of routine stability studies or 
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as a safety check to confirm the correct quantity has been added before it 
is administered to a patient. 
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Appendix 2 Contents of 500 ml bottle of Aminoven® 25 
 Amount (g) 
Alanine 12.5 
Arginine 10 
Glycine 9.25 
Histidine 3.65 
Isoleucine 2.6 
Leucine 4.45 
Lysine 5.55 
Methionine 1.9 
Phenylalanine 2.75 
Proline 8.5 
Serine 4.8 
Taurine 1 
Threonine 4.3 
Tryptophan 0.8 
Tyrosine 0.2 
Valine 2.75 
 
Appendix 3 Aqueous formulation used for initial HPLC work 
Constituents 
Volume 
(ml) 
Aminoven® 25  350.19 
Glucose 70% 428.57 
Additrace® (Fresenius Kabi, Runcorn, UK) 20 
Solivito® N (in Water for Injections) 20 
Sodium Chloride 30% 14.61 
Potassium Chloride 15% 38.53 
Potassium Acetate 49% 19.52 
Calcium Chloride 1 mmol/ml 40 
Magnesium Sulphate 50% 9.86 
Glycophos® (Fresenius Kabi, Runcorn, UK) 50 
Sodium Selenite 0.2 µmol/ml 2 
Water for Injections 6.71 
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Appendix 4 Peak areas from intermediate precision. The shaded column shows the 
anomalous injection 
 
Peak 
area 
1 
Peak 
area 
2 
Peak 
area 
3 
Peak 
area 
4 
Peak 
area 
5 
Peak 
area 
6 
Peak area 
6 
compared 
to mean 
of peak 
areas 1-5 
(%) 
Serine 2.895 2.759 2.823 2.696 2.854 2.437 86.87 
Glycine 8.619 8.148 8.293 7.843 8.201 7.083 86.16 
Threonine 2.1 2.057 2.142 2.002 2.19 1.821 86.79 
Arginine 4.496 4.235 4.318 4.079 4.331 3.694 86.07 
Alanine 9.085 8.509 8.704 8.234 8.706 7.44 86.04 
Taurine 0.694 0.655 0.671 0.644 0.681 0.587 87.74 
Tyrosine 0.076 0.083 0.085 0.094 0.128 0.124 133.05 
Valine 1.703 1.609 1.642 1.55 1.652 1.471 90.18 
Methionine 0.996 0.926 0.947 0.886 0.945 0.816 86.81 
Tryptophan 0.202 0.196 0.206 0.189 0.187 0.18 91.84 
Isoleucine 1.508 1.412 1.447 1.351 1.454 1.229 85.68 
Phenylalanine 1.238 1.167 1.189 1.14 1.214 1.035 87.00 
Leucine 2.781 2.69 2.945 2.579 2.776 2.379 86.38 
 
